NCT03040973
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03040973
Title Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DNK | DEU | CAN | BEL

Facility Status City State Zip Country Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Edmonton Alberta T6G 1Z2 Canada Details
Novartis Investigative Site Shanghai Shanghai Municipality 200433 China Details
Novartis Investigative Site Kunming Yunnan 650106 China Details
Novartis Investigative Site Copenhagen DK-2100 Denmark Details
Novartis Investigative Site Dijon Cote D Or 21034 France Details
Novartis Investigative Site Cologne North Rhine-Westphalia 50937 Germany Details
Novartis Investigative Site Hanover 30625 Germany Details
Novartis Investigative Site Milan MI 20141 Italy Details
Novartis Investigative Site Perugia PG 06129 Italy Details
Novartis Investigative Site Singapore 119074 Singapore Details
Novartis Investigative Site Seoul Korea 03080 South Korea Details
Novartis Investigative Site Seoul 05505 South Korea Details
Novartis Investigative Site Madrid 28040 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field